Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malign...

Full description

Bibliographic Details
Main Authors: Grandclément, C, Estoppey, C, Dheilly, E, Panagopoulou, M, Monney, T, Dreyfus, C, Loyau, J, Labanca, V, Drake, A, De Angelis, S, Rubod, A, Frei, J, Caro, LN, Blein, S, Martini, E, Chimen, M, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoelen, C, Pellat-Deceunynck, C, Moreau, P, Mbow, ML, Srivastava, A, Dyson, MR, Zhukovsky, EA, Perro, M, Sammicheli, S
Format: Journal article
Language:English
Published: Springer Nature 2024

Similar Items

Similar Items